Supplementary References
From Table 1:
55.
Bhalla K, Phillips HA, Crawford J, McKenzie OL, Mulley JC, Eyre H et al.
The de novo chromosome 16 translocations of two patients with abnormal
phenotypes (mental retardation and epilepsy) disrupt the A2BP1 gene. J
Hum Genet 2004; 49(6): 308-311.
56.
Martin CL, Duvall JA, Ilkin Y, Simon JS, Arreaza MG, Wilkes K et al.
Cytogenetic and molecular characterization of A2BP1/FOX1 as a
candidate gene for autism. Am J Med Genet B Neuropsychiatr Genet
2007 Oct 5; 144B(7): 869-876.
57.
Takahashi S, Cui YH, Han YH, Fagerness JA, Galloway B, Shen YC et al.
Association of SNPs and haplotypes in APOL1, 2 and 4 with
schizophrenia. Schizophr Res 2008 Sep; 104(1-3): 153-164.
58.
Kuljis RO, Xu Y, Aguila MC, Baltimore D. Degeneration of neurons,
synapses, and neuropil and glial activation in a murine Atm knockout
model of ataxia-telangiectasia. Proc Natl Acad Sci U S A 1997 Nov 11;
94(23): 12688-12693.
59.
Mavrou A, Tsangaris GT, Roma E, Kolialexi A. The ATM gene and ataxia
telangiectasia. Anticancer Res 2008 Jan-Feb; 28(1B): 401-405.
60.
Bakkaloglu B, O'Roak BJ, Louvi A, Gupta AR, Abelson JF, Morgan TM et
al. Molecular cytogenetic analysis and resequencing of contactin
associated protein-like 2 in autism spectrum disorders. American journal
of human genetics 2008 Jan; 82(1): 165-173.
61.
Kalscheuer VM, FitzPatrick D, Tommerup N, Bugge M, Niebuhr E,
Neumann LM et al. Mutations in autism susceptibility candidate 2 (AUTS2)
in patients with mental retardation. Human genetics 2007 May; 121(3-4):
501-509.
62.
Sultana R, Yu CE, Yu J, Munson J, Chen D, Hua W et al. Identification of
a novel gene on chromosome 7q11.2 interrupted by a translocation
breakpoint in a pair of autistic twins. Genomics 2002 Aug; 80(2): 129-134.
63.
Farrer LA, Abraham CR, Haines JL, Rogaeva EA, Song Y, McGraw WT et
al. Association between bleomycin hydrolase and Alzheimer's disease in
caucasians. Ann Neurol 1998 Nov; 44(5): 808-811.
64.
Sakurai K, Migita O, Toru M, Arinami T. An association between a
missense polymorphism in the close homologue of L1 (CHL1, CALL) gene
and schizophrenia. Molecular psychiatry 2002; 7(4): 412-415.
65.
Hashimoto R, Yoshida M, Kunugi H, Ozaki N, Yamanouchi Y, Iwata N et
al. A missense polymorphism (H204R) of a Rho GTPase-activating
protein, the chimerin 2 gene, is associated with schizophrenia in men.
Schizophr Res 2005 Mar 1; 73(2-3): 383-385.
66.
Alarcon M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV, Bomar JM
et al. Linkage, association, and gene-expression analyses identify
CNTNAP2 as an autism-susceptibility gene. American journal of human
genetics 2008 Jan; 82(1): 150-159.
67.
Arking DE, Cutler DJ, Brune CW, Teslovich TM, West K, Ikeda M et al. A
common genetic variant in the neurexin superfamily member CNTNAP2
increases familial risk of autism. American journal of human genetics 2008
Jan; 82(1): 160-164.
68.
Verkerk AJ, Mathews CA, Joosse M, Eussen BH, Heutink P, Oostra BA.
CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and
obsessive compulsive disorder. Genomics 2003 Jul; 82(1): 1-9.
69.
Lee HJ, Song JY, Kim JW, Jin SY, Hong MS, Park JK et al. Association
study of polymorphisms in synaptic vesicle-associated genes, SYN2 and
CPLX2, with schizophrenia. Behav Brain Funct 2005 Aug 31; 1: 15.
70.
Medina M, Marinescu RC, Overhauser J, Kosik KS. Hemizygosity of deltacatenin (CTNND2) is associated with severe mental retardation in cri-duchat syndrome. Genomics 2000 Jan 15; 63(2): 157-164.
71.
de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI,
Nelson DL et al. Rescue of behavioral phenotype and neuronal protrusion
morphology in Fmr1 KO mice. Neurobiol Dis 2008 Jul; 31(1): 127-132.
72.
Devon RS, Anderson S, Teague PW, Muir WJ, Murray V, Pelosi AJ et al.
The genomic organisation of the metabotropic glutamate receptor subtype
5 gene, and its association with schizophrenia. Molecular psychiatry 2001
May; 6(3): 311-314.
73.
Diaz-Anzaldua A, Joober R, Riviere JB, Dion Y, Lesperance P, Chouinard
S et al. Association between 7q31 markers and Tourette syndrome. Am J
Med Genet A 2004 May 15; 127A(1): 17-20.
74.
Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics 2004
May; 113(5): e472-486.
75.
Petek E, Schwarzbraun T, Noor A, Patel M, Nakabayashi K, Choufani S et
al. Molecular and genomic studies of IMMP2L and mutation screening in
autism and Tourette syndrome. Mol Genet Genomics 2007 Jan; 277(1):
71-81.
76.
Petek E, Windpassinger C, Vincent JB, Cheung J, Boright AP, Scherer
SW et al. Disruption of a novel gene (IMMP2L) by a breakpoint in 7q31
associated with Tourette syndrome. American journal of human genetics
2001 Apr; 68(4): 848-858.
77.
Bergametti F, Denier C, Labauge P, Arnoult M, Boetto S, Clanet M et al.
Mutations within the programmed cell death 10 gene cause cerebral
cavernous malformations. American journal of human genetics 2005 Jan;
76(1): 42-51.
78.
Novak G, Kim D, Seeman P, Tallerico T. Schizophrenia and Nogo:
elevated mRNA in cortex, and high prevalence of a homozygous CAA
insert. Brain Res Mol Brain Res 2002 Nov 15; 107(2): 183-189.
79.
Berry T. A selenium transport protein model of a sub-type of
schizophrenia. Med Hypotheses 1994 Dec; 43(6): 409-414.
80.
Crowther DC. Familial conformational diseases and dementias. Hum
Mutat 2002 Jul; 20(1): 1-14.
81.
Vawter MP, Shannon Weickert C, Ferran E, Matsumoto M, Overman K,
Hyde TM et al. Gene expression of metabolic enzymes and a protease
inhibitor in the prefrontal cortex are decreased in schizophrenia.
Neurochem Res 2004 Jun; 29(6): 1245-1255.
82.
Chahl LA. Tachykinins and neuropsychiatric disorders. Curr Drug Targets
2006 Aug; 7(8): 993-1003.